A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2022; you can also visit the original URL.
The file type is application/pdf
.
Therapeutic Benefit of Intracavitary-interstitial Brachytherapy in Cervical Cancer Patients with Small and Large High-risk Clinical Target Volume
2021
Turkish Journal of Oncology
We aimed to investigate the added value of interstitial brachytherapy (IS-BT) over classical intracavitary BT (IC-BT) in terms of target coverage and organ at risk (OAR) sparing among patients for whom an optimal dose distribution could not be provided without IS-ICBT and also to determine if the magnitude advantage provided by IS-BT is similar in patients smaller (<30 cm 3 ) and larger (≥30 cm 3 ) high-risk clinical target volume (CTV HR ). METHODS 24 patients treated with IS-ICBT were
doi:10.5505/tjo.2021.2837
fatcat:6wuxvvmw2jdszfswox4p2jkm4i